Interleukin Genetics (ILIU) 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 12, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Registrant Name	INTERLEUKIN GENETICS INC
Entity Central Index Key	1,037,649
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ILIU
Entity Common Stock, Shares Outstanding		229,329,744

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 1,274,366	$ 4,706,018
Accounts receivable from related party	49,027	39,989
Trade accounts receivable	3,755	45,973
Inventory	87,779	124,583
Prepaid expenses	621,679	778,970
Total current assets	2,036,606	5,695,533
Fixed assets, net	544,920	643,900
Intangible assets, net	42,154	58,879
Other assets	28,001	93,208
Total assets	2,651,681	6,491,520
Current liabilities:
Accounts payable	769,992	408,374
Accrued expenses	529,636	497,688
Deferred revenue	2,685,988	3,238,541
Short term debt	2,000,000	1,333,333
Total current liabilities	5,985,616	5,477,936
Long Term Debt	2,289,818	3,474,984
Total Liabilities	8,275,434	8,952,920
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.001 par value - 450,000,000 shares authorized; 173,029,840 and 172,887,221 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	173,032	172,889
Additional paid-in capital	126,796,476	126,354,036
Accumulated deficit	(132,593,261)	(128,988,325)
Total stockholders' equity	(5,623,753)	(2,461,400)
Total liabilities and stockholders' equity	$ 2,651,681	$ 6,491,520

CONDENSED BALANCE SHEETS _Paren

CONDENSED BALANCE SHEETS [Parenthetical] - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	173,029,840	172,887,221
Common stock, shares outstanding	173,029,840	172,887,221

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue:
Genetic testing	$ 349,396	$ 324,837	$ 611,865	$ 672,737
Other	240,813	51,214	939,262	106,526
Total revenue	590,209	376,051	1,551,127	779,263
Cost of revenue	355,177	331,555	882,123	662,596
Gross profit	235,032	44,496	669,004	116,667
Operating expenses:
Research and development	452,483	384,538	932,539	567,068
Selling, general and administrative	1,713,076	1,655,226	3,024,261	3,218,017
Amortization of intangibles	8,362	19,414	16,725	38,828
Total operating expenses	2,173,921	2,059,178	3,973,525	3,823,913
Loss from operations	(1,938,889)	(2,014,682)	(3,304,521)	(3,707,246)
Other income (expense):
Interest income	0	0	0	222
Interest expense	(109,958)	(113,750)	(223,708)	(226,250)
Interest expense Non-cash	(38,354)	(38,354)	(76,707)	(76,707)
Total other income (expense)	(148,312)	(152,104)	(300,415)	(302,735)
Loss before income taxes	(2,087,201)	(2,166,786)	(3,604,936)	(4,009,981)
Benefit for income taxes	0	0	0	0
Net loss	$ (2,087,201)	$ (2,166,786)	$ (3,604,936)	$ (4,009,981)
Basic and diluted net loss per common share	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted average common shares outstanding, basic and diluted	173,029,840	172,786,907	172,991,119	172,762,366

CONDENSED STATEMENTS OF STOCKHO

CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT - 6 months ended Jun. 30, 2016 - USD ($)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ (2,461,400)	$ 0	$ 172,889	$ 126,354,036	$ (128,988,325)
Balance (in shares) at Dec. 31, 2015		0	172,887,221
Net loss	(3,604,936)	$ 0	$ 0	0	(3,604,936)
Horizon warrant	5,924	0	0	5,924	0
Employee stock purchase plan	7,131	$ 0	$ 143	6,988	0
Employee stock purchase plan (in shares)		0	142,619
Stock-based compensation expense	429,528	$ 0	$ 0	429,528	0
Balance at Jun. 30, 2016	$ (5,623,753)	$ 0	$ 173,032	$ 126,796,476	$ (132,593,261)
Balance (in shares) at Jun. 30, 2016		0	173,029,840

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,604,936)	$ (4,009,981)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization	124,669	142,193
Amortization of loan issuance costs and fair value of warrants	52,631	55,593
Stock-based compensation expense	429,528	399,235
Changes in operating assets and liabilities:
Accounts receivable, net	42,218	6,390
Receivable from related party	(9,038)	(26,782)
Inventory	36,804	12,527
Prepaid expenses and other current assets	157,291	(61,194)
Accounts payable	361,618	(153,689)
Accrued expenses	4,113	33,191
Deferred revenue	(552,553)	(185,679)
Deferred liability	27,835	31,082
Net cash used in operating activities	(2,929,820)	(3,757,114)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital additions	(8,963)	(21,518)
Net cash used in investing activities	(8,963)	(21,518)
CASH FLOWS FROM FINANCING ACTIVITIES:
Private placement offering costs	0	(7,100)
Payment of notes payable	(500,000)	0
Proceeds from employee stock purchase plan	7,131	10,844
Net cash (used in) provided by financing activities	(492,869)	3,744
Net increase (decrease) in cash and cash equivalents	(3,431,652)	(3,774,888)
Cash and cash equivalents, beginning of period	4,706,018	11,466,807
Cash and cash equivalents, end of period	1,274,366	7,691,919
Cash paid for interest	$ 223,708	$ 237,500

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1—Basis of Presentation Interleukin Genetics, Inc. (“the Company”) develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive or therapeutic measures. The Company’s principal operations and markets are located in the United States. The accompanying condensed financial statements include the accounts of the Company as of June 30, 2016 and December 31, 2015 and for the three and six months ended June 30, 2016 and June 30, 2015. The financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial reporting. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. These unaudited condensed financial statements, which in the opinion of management reflect all adjustments (including normal recurring adjustments) necessary for a fair presentation, should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Operating results are not necessarily indicative of the results that may be expected for any future interim period or for the entire 2016 fiscal year. For information regarding our critical accounting policies and estimates, please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” contained in our Annual Report on Form 10-K for the year ended December 31, 2015 and Note 3 to our condensed financial statements contained herein.

Operating Matters and Liquidity

Operating Matters and Liquidity	6 Months Ended
	Jun. 30, 2016
Going Concern [Abstract]
Operating Matters and Liquidity	Note 2—Operating Matters and Liquidity The Company has experienced net operating losses since its inception through June 30, 2016. The Company had net losses of $ 7.9 6.3 3.6 132.6 The Company continues to take steps to reduce genetic test processing costs. Cost savings are primarily achieved through test process improvements. Management believes that the current laboratory space is adequate to process high volumes of genetic tests. On December 23, 2014, the Company entered into a Securities Purchase Agreement (the “2014 Purchase Agreement”) with various accredited investors (the “2014 Investors”), pursuant to which the Company sold to the 2014 Investors in a private placement transaction (the “December 2014 Private Placement”) an aggregate of 50,099,700 0.1003 5.025 50,099,700 0.1003 On December 23, 2014, the Company entered into a Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (the “Lender”) under which the Company has borrowed $ 5.0 The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month 9.0 The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable 2,492,523 0.1003 The Company’s financial statements have been prepared assuming that it will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments that might result from the outcome of this uncertain realization. The Company expects to incur additional losses in 2016 and, accordingly, is dependent on financings and potential revenue to fund its operations and support the market adoption of the PerioPredict ® 56,262,571 0.0994 5.6 (see Note 10—Subsequent Events to the financial statements). The Company expects the proceeds from this transaction, together with the cash the Company had on hand, to be sufficient to support the further commercialization of the PerioPredict The ability of the Company to realize the carrying value of its fixed assets and intangible assets is especially dependent on management’s ability to successfully execute on its plan. The Company needs to generate additional funds in order to meet its financial obligations. If it is unsuccessful in doing so, the Company may not be able to realize the carrying value of its fixed assets and intangible assets.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3—Summary of Significant Accounting Policies The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements. Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. For the six months ended June 30, 2016, the Company recognized $ 612,000 673,000 2.7 3.2 2.5 0.20 2.3 3.3 For the three and six months ended June 30, 2016, the Company recognized $ 241,000 939,000 51,000 107,000 829,000 109,000 The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2015 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the three and six months ended June 30, 2016 is $ 69,000 130,000 52,000 128,000 On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 85,000 80,000 152,000 168,000 Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2 Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve was deemed necessary at December 31, 2015 or June 30, 2016. As the Company does not manufacture any products, no overhead costs are included in inventory. Our inventory is stored at a fulfillment provider. All kit components held at the fulfillment center are reflected in inventory. June 30, 2016 December 31, 2015 Raw materials $ 69,580 $ 112,372 Finished goods 18,199 12,211 Total inventory, net $ 87,779 $ 124,583 The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $ 34.7 As a result of the Company’s change in its capital structure during the quarters ended June 30, 2013 and December 31, 2014, the Company may have undergone IRC section 382 ownership changes which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. The Company has not performed an analysis to determine the extent of such limitations, if any. The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the six months ended June 30, 2016. Research and development costs are expensed as incurred. The Company applies the provisions of FASB ASC 260, Earnings per Share As of June 30, 2016 2015 Options outstanding 22,062,770 22,288,867 Warrants outstanding 88,301,079 88,301,079 Total 110,363,849 110,589,946 The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model. The Company maintains its cash and cash equivalents with a domestic financial institution that the Company believes to be of high credit standing. The Company believes that, as of June 30, 2016, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits. Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. As of June 30, 2016 and 2015, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States. FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers. In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps: · Identify the contract(s) with a customer. · Identify the performance obligations in the contract. · Determine the transaction price. · Allocate the transaction price to the performance obligations in the contract. · Recognize revenue when (or as) the entity satisfies a performance obligation. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April, 2015 the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements. FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements—Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance. The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation. ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the impact of ASU 2014-15 on our financial disclosures, but are not electing early adoption at this time. FASB ASU 2016-02 - Leases (Topic 842). In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842). The updated standard aims to increase transparency and comparability among organizations by requiring lessees to recognize lease assets and lease liabilities on the balance sheet and requiring disclosure of key information about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements. FASB ASU No. 2016-09, - Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. In March 2016, the FASB issued ASU No. 2016-09. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 4—Related Party Transactions Since March 2003, the Company has maintained a broad strategic alliance with several affiliates of the Alticor Inc. family of companies, a related party. The alliance initially included an equity investment, a multi-year research and development agreement, a licensing agreement with royalties on marketed products, the deferment of outstanding loan repayment and the refinancing of bridge financing obligations. On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor. Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health brand of genetic tests through its e-commerce website via a hyperlink to our e-commerce site. The Company paid Amway Global $ 85,000 80,000 152,000 168,000 In 2012 and 2013, Access Business Group LLC (“ABG”), an affiliate of Alticor placed purchase orders totaling approximately $ 3.3 1.5 1.8 519,000 In October 2014, the Company received $ 250,000 On September 21, 2012, the Company entered into a License Agreement (the “License Agreement”) with Access Business Group International LLC (“ABGI”), an affiliate of Alticor. Pursuant to the License Agreement, the Company has granted ABGI and its affiliates a non-exclusive license to use the technology related to Interleukin’s Weight Management genetic test and to sell the Weight Management test in Europe, Russia and South Africa (the “Territories”). ABGI, or a laboratory designated by ABGI, will be responsible for processing the tests, and the Company will receive a royalty for each test sold, which royalty will increase if certain pending patent applications are issued. The License Agreement has an initial term of five years from the date of first commercial sale of the Weight Management test under the agreement which was in June 2013. Thereafter, the term will automatically renew for additional one-year periods unless at least 60 47,000 106,000 49,000 103,000 In connection with the execution of the License Agreement, the Company and ABGI also entered into a Professional Services Agreement (the “PSA”) pursuant to which the Company has agreed to provide services to ABGI in connection with its sale and processing of the tests within the Territories. No fees were earned in the six months ended June 30, 2016 or June 30, 2015. For the three months ended June 30, 2016 and 2015, approximately 37 46 5 16 23 51 4 15 On February 25, 2013, the Company entered into a Preferred Participation Agreement with Renaissance Health Services Corporation (“RHSC”), for itself and on behalf of certain of its affiliates and subsidiaries. This agreement was amended and restated on November 1, 2013. RHSC is a related party through its affiliation with Delta Dental of Michigan, Inc. (“DDMI”), a stockholder of the Company.

Debt Instruments

Debt Instruments	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Debt Instruments	Note 5—Debt Instruments Venture Loan and Security Agreement On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the “Lender”) under which the Company has borrowed $ 5.0 The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month 9.0 The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable 2,492,523 0.1003 Additionally, $ 88,918 261,386 225,000 210,000 110,000 224,000 124,000 238,000 38,000 77,000 38,000 77,000

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies [Abstract]
Commitments and contingencies	Note 6—Commitments and contingencies Operating Lease The Company leases its office and laboratory space under a non-cancelable operating lease which is scheduled to expire on March 31, 2017. The lease agreement includes an initial base rent beginning in March 2014 with an escalation of 2.06 2.06 Rent expense was $ 87,000 94,000 172,000 173,000 Off-Balance Sheet Arrangements The Company has no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on its financial condition, results of operations or cash flows.

Capital Stock

Capital Stock	6 Months Ended
	Jun. 30, 2016
Capital Stock [Abstract]
Capital Stock	Note 7—Capital Stock Authorized Preferred and Common Stock As of June 30, 2016, the Company has 6,000,000 0.001 450,000,000 0.001 Reserved Strike Expiry Shares reserved under outstanding stock options and options available for grant 52,107,279 Rights associated with Employee Stock Purchase Plan 157,454 Warrants to purchase common stock associated with December 2014 private placement 50,189,431 $ 0.1003 Dec 23, 2021 Warrants to purchase common stock associated with December 2014 venture loan and security agreement 2,492,523 $ 0.1003 Dec 23, 2024 Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors 100,000 $ 0.2500 Sept 8, 2024 Outstanding warrants issued in June 2012 437,158 $ 0.2745 June 29, 2017 Outstanding warrants issued in May 2013, vesting May 2013 20,655,737 $ 0.2745 May 17, 2020 Outstanding warrants issued in May 2013, vesting August 2013 14,426,230 $ 0.2745 Aug 9, 2020 Total common shares reserved for issuance at June 30, 2016 140,565,812 Total common shares issued and outstanding at June 30, 2016 173,029,840 Total common shares outstanding and reserved for issuance at June 30, 2016 313,595,652 On May 17, 2013, the Company entered into a Common Stock Purchase Agreement (the “2013 Purchase Agreement”) with various accredited investors (the “2013 Investors”), pursuant to which the Company sold securities to the 2013 Investors in a private placement transaction (the “May 2013 Private Placement”). In the May 2013 Private Placement, the Company sold an aggregate of 43,715,847 0.2745 12,000,000 32,786,885 0.2745 63 37 150,000,000 300,000,000 For its services in this transaction, the placement agent received cash compensation in the amount of approximately $ 780,000 2,295,082 0.2745 In connection with the May 2013 Private Placement, all preferred stockholders converted their shares of Preferred Stock to common stock resulting in the issuance of 39,089,161 14,316,255 2,521,222 In September 2014, the Company issued warrants to the Company’s financial consultant, Danforth Advisors, to purchase up to 100,000 0.25 50 24,000 3,000 6,000 On December 23, 2014, the Company entered into a Securities Purchase Agreement (the “2014 Purchase Agreement”) with various accredited investors (the “2014 Investors”), pursuant to which it sold to the 2014 Investors in a private placement transaction (the “December 2014 Private Placement”) an aggregate of 50,099,700 0.1003 5.025 50,099,700 0.1003 For services related to this transaction, the placement agent and legal counsel received an aggregate of $ 218,000 89,731 The 2014 Warrants and the 2014 Placement Agent Warrants were recorded as equity at fair value on the date of issuance. On the close date of the 2014 Purchase Agreement, the fair value of the 2014 Warrants was $ 5.2 9,000 Venture Loan and Security Agreement On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation under which the Company has borrowed $ 5.0 2,492,523 0.1003 The Lender Warrants were recorded as equity at fair value on the date of issuance. Fair value of the Lender Warrants was calculated using the Black-Scholes model. The fair value of the Lender Warrants at issuance was $ 261,000 110,000 224,000 124,000 238,000 38,000 77,000 38,000 77,000 210,000

Stock-Based Compensation Arrang

Stock-Based Compensation Arrangements	6 Months Ended
	Jun. 30, 2016
Stock-Based Compensation Arrangements [Abstract]
Stock-Based Compensation Arrangements	Note 8—Stock-Based Compensation Arrangements Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Stock option grants beginning of period $ 214,647 $ 141,383 $ 424,987 $ 239,823 Stock-based arrangements during the period: Stock option grants - 110,323 3,367 157,371 Restricted stock issued: Employee stock purchase plan 611 1,219 1,174 2,041 $ 215,258 $ 252,925 $ 429,528 $ 399,235 Stock option and restricted stock grants Six Months Ended Six Months Ended Shares Weighted Avg Shares Weighted Avg Outstanding, beginning of period 21,657,776 $ 0.21 4,523,900 $ 0.39 Stock options granted 1,185,400 0.05 17,779,027 0.17 Stock options exercised — 0.00 — 0.00 Restricted stock exercised — 0.00 — 0.00 Canceled/Expired (780,406) 0.33 (14,060) 0.28 Outstanding, end of period 22,062,770 $ 0.20 22,288,867 $ 0.28 Exercisable, end of period 8,211,111 $ 0.25 2,609,643 $ 0.36 As of June 30, 2016 and 2015, there was approximately $ 1.9 2.9 Restricted Stock Awards At June 30, 2016 and 2015, there were no outstanding restricted stock awards. Stock Option Grants On August 9, 2013, the Company’s shareholders’ approved the 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan”). The 2013 Plan allows for the issuance of up to 8,860,000 2,435,500 30,000,000 1,185,400 30,044,509 Pursuant to his employment agreement, on April 6, 2015, Mr. Carbeau was granted options to purchase up to 14,245,227 0.1525 2,622,948 11,622,279 It is the Company’s policy to grant stock options with an exercise price equal to the fair market value of the Company’s common stock at the grant date, and stock options to employees generally vest over four years based upon continuous service. Historically, the majority of the Company’s stock options have been granted in connection with the employee’s start date with the Company. In addition, the Company may grant stock options in recognition of promotion and/or performance. Employee Stock Purchase Plan Purchases made under the Company’s Employee Stock Purchase Plan are deemed to be compensatory because employees may purchase stock at a price equal to 85 142,619 103,565 0.05 0.11 0.06 0.13 1,174 2,041

Industry Risk and Concentration

Industry Risk and Concentration	6 Months Ended
	Jun. 30, 2016
Risks and Uncertainties [Abstract]
Industry Risk and Concentration	Note 9—Industry Risk and Concentration The Company develops genetic risk assessment tests and performs research for its own benefit. As of June 30, 2016, the Company sells five genetic risk assessment tests. Commercial success of the Company’s genetic risk assessment tests will depend on their success at being deemed to be scientifically credible and cost-effective by consumers and the marketing success of the Company and its collaborative partners. Research in the field of disease predisposing genes and genetic markers is intense and highly competitive. The Company has many competitors in the United States and abroad that have considerably greater financial, technical, marketing, and other resources available. If the Company does not discover disease predisposing genes or genetic markers and develop risk assessment tests and launch such services or products before its competitors, then the potential for significant revenues may be reduced or eliminated. During the three months ended June 30, 2016 and 2015, approximately 37 46 5 16 23 51 4 15

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Event	Note 10—Subsequent Events On July 12, 2016 the Company announced it had signed an agreement with Amway, a leading direct selling company, to provide Interleukin’s PerioPredict Genetic Risk Test and Patient Engagement Platform to Amway’s employees as part of an enhanced employee benefits plan. Under terms of the agreement, the Company will make PerioPredict available to Amway’s approximately 5,000 On July 29, 2016, the Company entered into a Securities Purchase Agreement (the “2016 Purchase Agreement”) with various accredited investors (the “2016 Investors”), pursuant to which the Company sold to the 2016 Investors in a private placement transaction (the “2016 Private Placement”) an aggregate of 56,262,571 0.0994 5.6 56,262,571 0.0994 Per his employment agreement, Mark Carbeau will be granted an option to purchase shares of the Company’s common stock equal to 5 25 2.083 On May 19, 2016, the Company entered into an employment agreement with Stephan Toutain for the position of Chief Commercial Officer beginning on August 15, 2016. The agreement provides for a minimum annual base salary of $ 315,000 30 1 25 2.083

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Significant Accounting Policies [Abstract]
Management Estimates	Management Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements.
Revenue Recognition	Revenue Recognition Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. For the six months ended June 30, 2016, the Company recognized $ 612,000 673,000 2.7 3.2 2.5 0.20 2.3 3.3 For the three and six months ended June 30, 2016, the Company recognized $ 241,000 939,000 51,000 107,000 829,000 109,000 The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2015 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the three and six months ended June 30, 2016 is $ 69,000 130,000 52,000 128,000
Sales Commissions	Sales Commission On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 85,000 80,000 152,000 168,000
Accounts Receivable	Accounts Receivable Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2
Inventory	Inventory Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve was deemed necessary at December 31, 2015 or June 30, 2016. As the Company does not manufacture any products, no overhead costs are included in inventory. Our inventory is stored at a fulfillment provider. All kit components held at the fulfillment center are reflected in inventory. June 30, 2016 December 31, 2015 Raw materials $ 69,580 $ 112,372 Finished goods 18,199 12,211 Total inventory, net $ 87,779 $ 124,583
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $ 34.7 As a result of the Company’s change in its capital structure during the quarters ended June 30, 2013 and December 31, 2014, the Company may have undergone IRC section 382 ownership changes which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. The Company has not performed an analysis to determine the extent of such limitations, if any. The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the six months ended June 30, 2016.
Research and Development	Research and Development Research and development costs are expensed as incurred.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share The Company applies the provisions of FASB ASC 260, Earnings per Share As of June 30, 2016 2015 Options outstanding 22,062,770 22,288,867 Warrants outstanding 88,301,079 88,301,079 Total 110,363,849 110,589,946
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company maintains its cash and cash equivalents with a domestic financial institution that the Company believes to be of high credit standing. The Company believes that, as of June 30, 2016, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits.
Fixed Assets	Fixed Assets Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease.
Segment Reporting	Segment Reporting As of June 30, 2016 and 2015, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States.
Recent Accounting Pronouncements	Recent Accounting Pronouncements FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers. In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps: · Identify the contract(s) with a customer. · Identify the performance obligations in the contract. · Determine the transaction price. · Allocate the transaction price to the performance obligations in the contract. · Recognize revenue when (or as) the entity satisfies a performance obligation. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April, 2015 the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements. FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements—Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance. The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation. ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the impact of ASU 2014-15 on our financial disclosures, but are not electing early adoption at this time. FASB ASU 2016-02 - Leases (Topic 842). In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842). The updated standard aims to increase transparency and comparability among organizations by requiring lessees to recognize lease assets and lease liabilities on the balance sheet and requiring disclosure of key information about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements. FASB ASU No. 2016-09, - Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. In March 2016, the FASB issued ASU No. 2016-09. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2016
Significant Accounting Policies [Abstract]
Inventory	Inventory consisted of the following: June 30, 2016 December 31, 2015 Raw materials $ 69,580 $ 112,372 Finished goods 18,199 12,211 Total inventory, net $ 87,779 $ 124,583
Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share	Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows: As of June 30, 2016 2015 Options outstanding 22,062,770 22,288,867 Warrants outstanding 88,301,079 88,301,079 Total 110,363,849 110,589,946

Capital Stock (Tables)

Capital Stock (Tables)	6 Months Ended
	Jun. 30, 2016
Authorized, Issued and Reserved shares of common stock	As of June 30, 2016 the Company has 173,029,840 shares of common stock outstanding and the following shares of common stock are reserved for issuance: Reserved Strike Expiry Shares reserved under outstanding stock options and options available for grant 52,107,279 Rights associated with Employee Stock Purchase Plan 157,454 Warrants to purchase common stock associated with December 2014 private placement 50,189,431 $ 0.1003 Dec 23, 2021 Warrants to purchase common stock associated with December 2014 venture loan and security agreement 2,492,523 $ 0.1003 Dec 23, 2024 Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors 100,000 $ 0.2500 Sept 8, 2024 Outstanding warrants issued in June 2012 437,158 $ 0.2745 June 29, 2017 Outstanding warrants issued in May 2013, vesting May 2013 20,655,737 $ 0.2745 May 17, 2020 Outstanding warrants issued in May 2013, vesting August 2013 14,426,230 $ 0.2745 Aug 9, 2020 Total common shares reserved for issuance at June 30, 2016 140,565,812 Total common shares issued and outstanding at June 30, 2016 173,029,840 Total common shares outstanding and reserved for issuance at June 30, 2016 313,595,652

Stock-Based Compensation Arra20

Stock-Based Compensation Arrangements (Tables)	6 Months Ended
	Jun. 30, 2016
Stock-Based Compensation Arrangements [Abstract]
Total Compensation Cost Recorded for Stock-Based Compensation	Total stock-based compensation is as follows: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Stock option grants beginning of period $ 214,647 $ 141,383 $ 424,987 $ 239,823 Stock-based arrangements during the period: Stock option grants - 110,323 3,367 157,371 Restricted stock issued: Employee stock purchase plan 611 1,219 1,174 2,041 $ 215,258 $ 252,925 $ 429,528 $ 399,235
Schedule of Stock option activity	The following table details stock option activity: Six Months Ended Six Months Ended Shares Weighted Avg Shares Weighted Avg Outstanding, beginning of period 21,657,776 $ 0.21 4,523,900 $ 0.39 Stock options granted 1,185,400 0.05 17,779,027 0.17 Stock options exercised — 0.00 — 0.00 Restricted stock exercised — 0.00 — 0.00 Canceled/Expired (780,406) 0.33 (14,060) 0.28 Outstanding, end of period 22,062,770 $ 0.20 22,288,867 $ 0.28 Exercisable, end of period 8,211,111 $ 0.25 2,609,643 $ 0.36

Operating Matters and Liquidi21

Operating Matters and Liquidity - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 29, 2016	Dec. 23, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Net Income Loss			$ (2,087,201)	$ (2,166,786)	$ (3,604,936)	$ (4,009,981)	$ 7,900,000	$ 6,300,000
Accumulated deficit			$ (132,593,261)		$ (132,593,261)		$ (128,988,325)
Venture Loan [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,492,523
Debt Instrument, Payment Terms		The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable
Proceeds from Issuance of Long-term Debt		$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage		9.00%	9.00%		9.00%
Warrants Expire Term		10 years
Venture Loan [Member] | Horizon Technology Finance Corporation [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Description of Variable Rate Basis		The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month
December 2014 Private Placement [Member]
Line of Credit Facility [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		50,099,700
Sale of Stock, Price Per Share		$ 0.1003
Sale of Stock, Consideration Received on Transaction		$ 5,025,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.1003		$ 0.1003
2014 warrants [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		50,099,700
Warrants Expire Term		7 years
Common Stock [Member]
Line of Credit Facility [Line Items]
Net Income Loss					$ 0
Common Stock [Member] | Private Placement [Member] | Subsequent Event [Member]
Line of Credit Facility [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	56,262,571
Sale of Stock, Price Per Share	$ 0.0994
Sale of Stock, Consideration Received on Transaction	$ 5,600,000

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Schedule Of Inventory) (Detail) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Line Items]
Raw materials	$ 69,580	$ 112,372
Finished goods	18,199	12,211
Total inventory, net	$ 87,779	$ 124,583

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share) (Detail) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	110,363,849	110,589,946
Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	22,062,770	22,288,867
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	88,301,079	88,301,079

Summary of Significant Accoun24

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Significant Accounting Policies [Line Items]
Deferred revenue	$ 2,700,000		$ 2,700,000		$ 3,200,000
Sales commissions	85,000	$ 80,000	$ 152,000	$ 168,000
Percentage of cash discount offered to customers			2.00%
Deferred tax assets, valuation allowance	34,700,000		$ 34,700,000
Revenue Recognition, Milestone Method, Revenue Recognized			612,000	673,000
Other Sales Revenue Net	240,813	51,214	939,262	106,526
Contracts Revenue			829,000
License and Services Revenue			109,000
ABG [Member]
Significant Accounting Policies [Line Items]
Purchase Order Placed			3,300,000
Genetic Test Revenue [Member]
Significant Accounting Policies [Line Items]
Breakage Revenue	69,000	$ 52,000	130,000	$ 128,000
Customer Payment [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	200,000		200,000
Kits Components [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	2,500,000		2,500,000
Distributors [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	$ 2,300,000		$ 2,300,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Oct. 31, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2013
Business Acquisition [Line Items]
Prior Period Notice				60 days
Proceeds from License Fees Received		$ 47,000	$ 49,000	$ 106,000	$ 103,000
Business Combination, Consideration Transferred	$ 250,000
Amway Global [Member]
Business Acquisition [Line Items]
Commissions paid		$ 85,000	$ 80,000	$ 152,000	$ 168,000
Concentration Risk, Percentage		37.00%	46.00%
Amway Global [Member] | Sales [Member]
Business Acquisition [Line Items]
Concentration Risk, Percentage				23.00%	51.00%
ABG [Member]
Business Acquisition [Line Items]
Concentration Risk, Percentage		5.00%	16.00%
Purchase Order Placed				$ 3,300,000
Payments to Acquire Businesses, Gross				$ 519,000
ABG [Member] | Sales [Member]
Business Acquisition [Line Items]
Concentration Risk, Percentage				4.00%	15.00%
ABG [Member] | 2014 Program [Member]
Business Acquisition [Line Items]
Purchase Order Received						$ 1,800,000
ABG [Member] | 2013 Program [Member]
Business Acquisition [Line Items]
Purchase Order Received						$ 1,500,000

Debt Instruments - Additional I

Debt Instruments - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 23, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Interest Paid				$ 223,708	$ 237,500
Venture Loan [Member]
Debt Instrument [Line Items]
Proceeds from Issuance of Long-term Debt	$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage	9.00%	9.00%		9.00%
Debt Instrument, Payment Terms	The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,492,523
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.1003
Warrants Expire Term	10 years
Interest Expense, Debt	$ 88,918
Intrinsic Value Of Warrants	261,386
Interest Expense, Other	$ 225,000
Debt Instrument, Unamortized Discount		$ 210,000		$ 210,000
Interest Paid		110,000	$ 124,000	224,000	238,000
Paid-in-Kind Interest		$ 38,000	$ 38,000	$ 77,000	$ 77,000
Venture Loan [Member] | Horizon Technology Finance Corporation [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis	The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Loss Contingencies [Line Items]
Operating Leases, Rent Expense	$ 87,000	$ 94,000	$ 172,000	$ 173,000
Operating Leases Base rent In Year Two			2.06%
Operating Leases Base Rent In Year Three			2.06%

Capital Stock (Authorized, Issu

Capital Stock (Authorized, Issued and Reserved shares of common stock) (Detail)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Reserved for issuance	140,565,812
Total common shares issued and outstanding at June 30, 2016	173,029,840
Total common shares outstanding and reserved for issuance at June 30, 2016	313,595,652
Warrants with common stock additional purchase rights associated with December 2014 private placement [Member]
Reserved for issuance	50,189,431
Strike Price | $ / shares	$ 0.1003
Expiry	Dec. 23, 2021
Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors [Member]
Reserved for issuance	100,000
Strike Price | $ / shares	$ 0.2500
Expiry	Sep. 8, 2024
Shares reserved under outstanding stock options and options available for grant [Member]
Reserved for issuance	52,107,279
Shares reserved for future issuance under the Employee Stock Purchase Plan [Member]
Reserved for issuance	157,454
Warrants to purchase common stock associated with December 2014 venture loan and security agreement [Member]
Reserved for issuance	2,492,523
Strike Price | $ / shares	$ 0.1003
Expiry	Dec. 23, 2024
Outstanding warrants issued in June 2012 [Member]
Reserved for issuance	437,158
Strike Price | $ / shares	$ 0.2745
Expiry	Jun. 29, 2017
Outstanding warrants issued in May 2013, vesting May 2013 [Member]
Reserved for issuance	20,655,737
Strike Price | $ / shares	$ 0.2745
Expiry	May 17, 2020
Outstanding warrants issued in May 2013, vesting August 2013 [Member]
Reserved for issuance	14,426,230
Strike Price | $ / shares	$ 0.2745
Expiry	Aug. 9, 2020

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended		6 Months Ended
	Dec. 23, 2014	Sep. 30, 2014	May 17, 2013	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Aug. 09, 2013
Stockholders Equity [Line Items]
Convertible preferred stock, par value				$ 0.001		$ 0.001
Convertible preferred stock, shares authorized				6,000,000		6,000,000
Common stock, shares authorized				450,000,000		450,000,000		450,000,000
Common stock, par value				$ 0.001		$ 0.001		$ 0.001
Allocated Share-based Compensation Expense				$ 3,000	$ 3,000	$ 6,000	$ 6,000
Common Stock Shares Issued				173,029,840		173,029,840		172,887,221
Debt Conversion, Converted Instrument, Shares Issued						2,521,222
Interest Paid						$ 223,708	237,500
Debt Conversion, Original Debt, Amount						14,316,255
May 2013 Private Placement [Member] | Minimum [Member]
Stockholders Equity [Line Items]
Common stock, shares authorized									150,000,000
May 2013 Private Placement [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Common stock, shares authorized									300,000,000
Venture Loan [Member]
Stockholders Equity [Line Items]
Warrants exercise price per share	$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,492,523
Warrants and Rights Outstanding				$ 261,000		$ 261,000
Proceeds from Issuance of Long-term Debt	$ 5,000,000
Warrants Expiration Term						10 years
Interest Paid				110,000	124,000	$ 224,000	238,000
Paid-in-Kind Interest				38,000	$ 38,000	77,000	$ 77,000
Debt Instrument, Unamortized Discount				$ 210,000		$ 210,000
Investor [Member]
Stockholders Equity [Line Items]
Sale of Stock, Consideration Received on Transaction	$ 5,025,000
Sale of Stock, Number of Shares Issued in Transaction	50,099,700
Warrants exercise price per share	$ 0.1003
Sale of Stock, Price Per Share	$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	50,099,700
Danforth Advisors [Member]
Stockholders Equity [Line Items]
Common stock, par value		$ 0.25
Warrants Fair Value Disclosure		$ 24,000
Common Stock Shares Issued		100,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Common Stock [Member]
Stockholders Equity [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion				39,089,161		39,089,161
Common Stock [Member] | May 2013 Private Placement [Member]
Stockholders Equity [Line Items]
Sale of Stock, Consideration Received on Transaction			$ 12,000,000
Sale of Stock, Number of Shares Issued in Transaction			43,715,847
Sale of Stock, Price Per Share			$ 0.2745
Warrants 2013 [Member]
Stockholders Equity [Line Items]
Percentage Of Warrants Exercisable			63.00%
Percentage Of Warrants Exercisable After Shareholder Approval			37.00%
Warrants exercise price per share			$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			32,786,885
Warrants 2014 [Member]
Stockholders Equity [Line Items]
Warrants and Rights Outstanding				$ 5,200,000		$ 5,200,000
Placement Agent Warrants [Member]
Stockholders Equity [Line Items]
Allocated Share-based Compensation Expense						$ 780,000
Warrants To Purchase Of Common Stock						2,295,082
Warrants exercise price per share				$ 0.2745		$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				89,731		89,731
Warrants and Rights Outstanding				$ 9,000		$ 9,000
Payments for Underwriting Expense						$ 218,000

Stock-Based Compensation Arra30

Stock-Based Compensation Arrangements (Stock-Based Compensation) (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation	$ 215,258	$ 252,925	$ 429,528	$ 399,235
Stock option grants beginning of period [Member]
Share-based Compensation	214,647	141,383	424,987	239,823
Stock option grants [Member]
Share-based Compensation	0	110,323	3,367	157,371
Employee Stock Purchase Plan [Member]
Share-based Compensation	$ 611	$ 1,219	$ 1,174	$ 2,041

Stock-Based Compensation Arra31

Stock-Based Compensation Arrangements (Stock Option and Restricted Stock Grants) (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Shares
Outstanding, beginning of period	21,657,776	4,523,900
Stock options granted	1,185,400	17,779,027
Stock options exercised	0	0
Restricted stock exercised	0	0
Cancelled/Expired	(780,406)	(14,060)
Outstanding, end of period	22,062,770	22,288,867
Exercisable, end of period	8,211,111	2,609,643
Weighted Avg. Exercise Price
Outstanding, beginning of period	$ 0.21	$ 0.39
Stock options granted	0.05	0.17
Stock options exercised	0	0
Restricted stock exercised	0	0
Cancelled/Expired	0.33	0.28
Outstanding, end of period	0.2	0.28
Exercisable, end of period	$ 0.25	$ 0.36

Stock-Based Compensation Arra32

Stock-Based Compensation Arrangements - Additional Information (Detail) - USD ($)	Apr. 06, 2015	Jul. 21, 2015	Jun. 30, 2016	Jun. 30, 2015	Aug. 09, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options			$ 1,900,000	$ 2,900,000
Granted,Weighted Avg.Exercise Price			$ 0.05	$ 0.17
Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	14,245,227
Granted,Weighted Avg.Exercise Price	$ 0.1525
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans			142,619
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock purchase price			85.00%
Weighted-average purchase price			$ 0.05	0.11
Weighted-average fair value			$ 0.06	$ 0.13
Compensation expense			$ 1,174	$ 2,041
Employee Stock Purchase Plan [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans			142,619	103,565
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Payment Award, Number of Shares Authorized					8,860,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		30,000,000	1,185,400
2013 Plan [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,622,948
2013 Plan [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			30,044,509
2004 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Payment Award, Number of Shares Authorized					2,435,500
Outside of 2013 Plan [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	11,622,279

Industry Risk and Concentrati33

Industry Risk and Concentration - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Amway Global [Member]
Sales Revenue Goods Net Percentage	37.00%	46.00%	23.00%	51.00%
ABG’s Promotional Product Bundle Program [Member]
Sales Revenue Goods Net Percentage	5.00%	16.00%	4.00%	15.00%

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Jul. 12, 2016	Aug. 31, 2016	Jul. 29, 2016USD ($)$ / sharesshares	May 19, 2016USD ($)
Mr.Toutain [Member]
Subsequent Event [Line Items]
Share Based Compensation Arrangement By Share Based Payment, Granted Percentage Of Common Stock Shares Diluted				1.00%
Salaries, Wages and Officers' Compensation | $				$ 315,000
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage				30.00%
Mr.Toutain [Member] | Share-based Compensation Award, Tranche One [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				25.00%
Mr.Toutain [Member] | Share-based Compensation Award, Tranche Two [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				2.083%
Subsequent Event [Member]
Subsequent Event [Line Items]
Defined Contribution Plan, Number of Employees Covered	5,000
Subsequent Event [Member] | Warrants 2016 [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			56,262,571
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.0994
Subsequent Event [Member] | Common Stock [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Sale of Stock, Price Per Share | $ / shares			$ 0.0994
Sale of Stock, Number of Shares Issued in Transaction | shares			56,262,571
Sale of Stock, Consideration Received on Transaction | $			$ 5,600,000
Subsequent Event [Member] | Mark Carbeau [Member]
Subsequent Event [Line Items]
Share Based Compensation Arrangement By Share Based Payment, Granted Percentage Of Common Stock Shares Issued		5.00%
Subsequent Event [Member] | Mark Carbeau [Member] | Share-based Compensation Award, Tranche One [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Subsequent Event [Member] | Mark Carbeau [Member] | Share-based Compensation Award, Tranche Two [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		2.083%